Latest news

The Japanese Cancer Association and Debiopharm Group™present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for their outstanding oncology…

Debiopharm Group™ and Aurigene nominate development candidate

Professor Leroux from ETH receives the Debiopharm Life Sciences Award 2010

Debiopharm Group™ starts Phase I clinical trial with Debio 0932

Two New Tenants for EPFL’s Innovation Square

Debiopharm Group™ and Biocartis embark on a partnership aiming at enhancing personalized medicine

Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 – A potent, first-in-class antiviral…

Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent…

Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanoma